Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5133- ART/DHA,    Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, U251
AntiTum↑, tumCV↓, Apoptosis↓, MMP↓, Cyt‑c↑, Casp9↑, CHOP/DDIT3↑, GRP78/BiP↑, eIF2α↑, Casp12↑, ER Stress↑, TumAuto↑, ROS↑,
5132- ART/DHA,    Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF7
Iron↓, TfR1/CD71↓, ROS↑,
5131- ART/DHA,    Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells
- in-vitro, NSCLC, ASTC-a-1
Apoptosis↑, MMP↓, Casp3↑, TumCP↓,
5130- ART/DHA,    Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway
- in-vitro, Bladder, T24/HTB-9
tumCV↓, eff↓, Apoptosis↑, Casp3↑, ROS↑, Cyt‑c↑, MMP↓, Bcl-2↓, BAX↑, MOMP↑, TumCG↓,
4991- ART/DHA,  doxoR,    Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
- in-vivo, Nor, H9c2
*cardioP↑, *ROS↓, *Ferroptosis↓, *NRF2↑, Keap1↓,
4992- ART/DHA,    Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway
- in-vitro, AML, HL-60
Apoptosis↑, Diff↑, ROS↓, HO-1↓, NRF2∅,
4993- ART/DHA,    Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway
- vitro+vivo, GC, NA
Ferroptosis↑, NRF2↓, HO-1↓, PI3K↓, Akt↓, TumMeta↓,
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
angioG↓, TumCG↓, VEGF↓, VEGFR2/KDR/Flk1↓, *toxicity↓,
1148- ART/DHA,    Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages
- in-vitro, AML, THP1
MMP9↓, EMMPRIN↓, p‑PKCδ↓, p‑JNK↓, p‑p38↓, p‑ERK↓,
573- ART/DHA,    Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model
- vitro+vivo, NA, NA
p‑p38↓, p‑ERK↓, p‑CREB↓, p‑Chk2↓, p‑STAT5↓, p‑RSK↓, SOCS1↑, Apoptosis↑, Casp3↑,
576- ART/DHA,    Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome
- Analysis, NA, NA
GSTP1/GSTπ↓, TfR1/CD71↓,
575- ART/DHA,    Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
- in-vitro, GBM, U87MG
GPx4↓, xCT∅, ROS↑, Ferroptosis↑, ACSL4∅,
574- ART/DHA,    Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway
TumCP↓, TumCMig↓, TumCI↓, MMP17↓, p‑EGFR↓, p‑Akt↓,
572- ART/DHA,    High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism
CSCs↓, mtDam↑,
571- ART/DHA,  TMZ,    Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
- vitro+vivo, GBM, A172 - vitro+vivo, GBM, U87MG
HR↓, RAD51↓, Apoptosis↑, necrosis↑, ROS↑, ChemoSen↑,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
561- ART/DHA,    Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo
- in-vivo, NA, NA
TumCG↓, CD4+↓, CD25+↓, FoxP3+↓, IL4↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, VEGFR2/KDR/Flk1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
557- ART/DHA,    Artemisinin and Its Derivatives in Cancer Care
- Review, Var, NA
*BioAv↓, *BioAv↑, Apoptosis↑, EGFR↓, CD31↓, Ki-67↓, P53↓, TfR1/CD71↑, P-gp↓, PD-1↝,
555- ART/DHA,    Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action
- Review, NA, NA
STAT3↓,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
559- ART/DHA,    Artemisinin and its derivatives: a promising cancer therapy
- Review, NA, NA
ROS↑,
560- ART/DHA,    Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo
- in-vivo, NA, NA
IL4↓, CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓,
562- ART/DHA,    Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression
- in-vivo, NA, HeLa
CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓, PGE2↓, FOXP3↓, COX2↓,
563- ART/DHA,    Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10
- in-vitro, Colon, colon26 - in-vitro, CRC, RKO
TGF-β↓, IL10↓,
564- ART/DHA,  Cisplatin,    Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling
- in-vitro, NA, HN30
JAK2↓, STAT3↓, MMP2↓, MMP9↓, Mcl-1↓, Bcl-xL↓, cycD1/CCND1↓, VEGF↓, TumCCA↑, ChemoSen↑,
565- ART/DHA,    Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma
STAT↓, IL6↓, pro‑Casp3↝, Bcl-xL↝, survivin↝,
566- ART/DHA,  2DG,    Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
GlucoseCon↓, ATP↓, lactateProd↓, p‑S6↓, mTOR↓, GLUT1↓, Casp9↑, Casp8↑, Casp3↑, Cyt‑c↑, AIF↑, ROS↑,
569- ART/DHA,    Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3
- in-vitro, GBM, NA
TumCP↓, Apoptosis↑, TumCCA↑, Casp3↑, p‑Akt↓,
567- ART/DHA,    An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells
- in-vitro, Lung, BEAS-2B
NRF2↑, AP-1↑, NFAT↑,
568- ART/DHA,    Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity
- in-vitro, NA, MDA-MB-231 - in-vitro, NA, HeLa - in-vitro, NA, SkBr3 - in-vitro, NA, HCT116
Iron↝,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑, NRF2↓,
1079- ART/DHA,    Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2
- in-vitro, GC, BGC-823 - in-vitro, GC, HGC27 - in-vitro, GC, MGC803
TumCP↓, Apoptosis↑, COX2↓, BAX↑, Bcl-2↓, Casp3↑, Casp9↑, MMP↓,
1099- ART/DHA,    Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
- in-vitro, NA, NA
EMT↓, TumCI↓, STAT3↓, β-catenin/ZEB1↓,
1075- ART/DHA,    Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer
- in-vitro, Nor, L929
*TGF-β↓,
1074- ART/DHA,    Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells
- in-vitro, Nor, BV2
*TNF-α↓, *IL6↓, *MCP1/CCL2↓, *NO↓, *iNOS↓, *IκB↑,
1026- ART/DHA,    Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
Ferroptosis↑, ROS↑, ERK↓, PD-L1↓,
957- ART/DHA,    Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels
- in-vitro, ESCC, KYSE150 - in-vitro, ESCC, KYSE170
TumCP↓, TumMeta↓, Glycolysis↓, N-cadherin↓, PKM2↓, Hif1a↓,
976- ART/DHA,    Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells
- in-vitro, BC, MCF7
ERα/ESR1↓,
985- ART/DHA,    Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway
- in-vitro, Thyroid, TPC-1 - Human, NA, NA
XIST↓, Hif1a↓, Glycolysis↓, TumCCA↑, TumMeta↓,
5381- ART/DHA,    Artemisitene triggers calcium-dependent ferroptosis by disrupting the LSH-EWSR1 interaction in colorectal cancer
- in-vitro, CRC, HCT116 - in-vitro, Nor, NCM460 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT8
Ferroptosis↑, CYP24A1↓, Ca+2↑, SCD1↓, FAO↑, lipid-P↑, eff↑, selectivity↑, other?,
5383- ART/DHA,    Artesunate is a drug used to treat severe malaria.
- Review, Var, NA
Half-Life?,
5382- ART/DHA,    A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies
- Trial, Var, NA
AntiCan↑, Dose↝, Dose↝,
5380- ART/DHA,    Artemisinin and Its Derivatives as Potential Anticancer Agents
- Review, Var, NA
TumCG↓, angioG↓, Ferroptosis↑, TumCP↑, TumAuto↑, CSCs↑, eff↑, YAP/TEAD↓, TumCCA↑, ROS↑, ChemoSen↑, N-cadherin↓, Vim↓, MMP9↓, eff↑, STAT3↓, CD133↓, CD44↓, Nanog↓, cMyc↓, OCT4↓, Akt↓, mTOR↓,
5379- ART/DHA,    Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance—from immune microenvironment crosstalk to therapeutic translation
Ferritin↓, Iron↑, Fenton↑, lipid-P↑, ChemoSen↑, ROS↑, eff↝,
5378- ART/DHA,    Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives
- Review, Var, NA
Ferroptosis↑, Iron↑, lipid-P↑, MOMP↑, AntiCan↑, NCOA4↑, GSH↓, GPx4↓, ROS↑, ChemoSen↑, ER Stress↑, DNAdam↑, angioG↓, TumCCA↑, eff↓,
5377- ART/DHA,    Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein
- in-vitro, AML, NA
AntiCan↑, Ferroptosis↑, Iron↑, Mets↑, eff↑, GSH↝, eff↑, other↓, eff↑, other↓,
5376- ART/DHA,    Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, SW48 - in-vitro, BC, MDA-MB-453
Ferroptosis↑, Ferritin↓, Iron↑, eff↑, TumAuto↑, LC3II↑, ROS↑,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5416- ASA,    Cancer Incidence and Mortality With Aspirin in Older Adults
- Trial, Var, NA
Risk∅, OS∅,

Showing Research Papers: 851 to 900 of 7361
Prev Page 18 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7361

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Fenton↑, 2,   Ferroptosis↑, 10,   GPx4↓, 2,   GSH↓, 1,   GSH↝, 1,   GSTP1/GSTπ↓, 1,   HO-1↓, 2,   Iron↓, 1,   Iron↑, 4,   Iron↝, 1,   i-Iron↓, 1,   Keap1↓, 1,   lipid-P↑, 4,   Mets↑, 1,   NRF2↓, 2,   NRF2↑, 2,   NRF2∅, 1,   ROS↓, 1,   ROS↑, 16,   xCT∅, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 2,   NCOA4↑, 1,   TfR1/CD71↓, 2,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   MMP↓, 4,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4∅, 1,   AMP↓, 1,   AMPK↑, 1,   cMyc↓, 2,   p‑CREB↓, 1,   FAO↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   PKM2↓, 1,   p‑S6↓, 1,   SCD1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   p‑Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 10,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Bcl-xL↝, 1,   Casp12↑, 1,   Casp3↑, 6,   pro‑Casp3↝, 1,   Casp8↑, 1,   Casp9↑, 3,   p‑Chk2↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 3,   Ferroptosis↑, 10,   p‑JNK↓, 1,   Mcl-1↓, 1,   MOMP↑, 2,   Myc↓, 1,   necrosis↑, 1,   oncosis↑, 2,   p27↑, 1,   p‑p38↓, 2,   p‑RSK↓, 1,   survivin↓, 1,   survivin↝, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 1,   other↓, 2,   other↝, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   TumAuto↑, 6,  

DNA Damage & Repair(tgid=10) ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 2,   HR↓, 2,   p16↑, 1,   P53↓, 1,   RAD51↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 2,   cycE1↓, 1,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CD44↓, 1,   cMET↓, 1,   CREBBP↓, 1,   CSCs↓, 2,   CSCs↑, 1,   Diff↑, 1,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 2,   mTOR↓, 4,   mTOR↑, 1,   Nanog↓, 2,   OCT4↓, 2,   P70S6K↑, 1,   PI3K↓, 2,   SOX2↓, 1,   STAT↓, 1,   STAT3↓, 4,   p‑STAT5↓, 1,   TumCG↓, 5,   Wnt/(β-catenin)↓, 2,   Wnt/(β-catenin)↑, 1,  

Migration(tgid=13) ⓘ

AP-1↑, 1,   Ca+2↑, 1,   CD31↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 2,   EMMPRIN↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   LysoPr↑, 1,   MMP17↓, 1,   MMP2↓, 2,   MMP9↓, 3,   N-cadherin↓, 3,   NCAM↑, 1,   NFAT↑, 1,   p‑PKCδ↓, 1,   TGF-β↓, 2,   TIMP2↑, 1,   Treg lymp↓, 2,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 5,   TumCP↑, 1,   TumMeta↓, 3,   Vim↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↓, 3,   CD4+↓, 3,   COX2↓, 2,   FOXP3↓, 1,   FoxP3+↓, 3,   IL1↓, 1,   IL10↓, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 2,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 2,   PD-1↝, 1,   PD-L1↓, 1,   PGE2↓, 2,   SOCS1↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CYP24A1↓, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 6,   Dose↝, 2,   eff↓, 2,   eff↑, 7,   eff↝, 1,   Half-Life?, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   Ferritin↓, 2,   IL6↓, 2,   Ki-67↓, 1,   Myc↓, 1,   PD-L1↓, 1,   XIST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   OS∅, 1,   Risk↓, 1,   Risk∅, 1,  
Total Targets: 189

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↓, 1,   NRF2↑, 1,   ROS↓, 1,  

Cell Death(tgid=5) ⓘ

Ferroptosis↓, 1,   iNOS↓, 1,  

Migration(tgid=13) ⓘ

TGF-β↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   IκB↑, 1,   MCP1/CCL2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   toxicity↓, 1,  
Total Targets: 16

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page